C5a Receptor Expression - COVID-19 (C5-COV)

计划入组 61 人 · 首次发布于 2020 年 4 月 30 日

Complement C5a Receptors in Hidradenitis Suppurativa

计划入组 34 人 · 首次发布于 2020 年 2 月 5 日

Study of the C5a/C5aR1 Axis in IgG4-associated Disease: a Potential Therapeutic Target

计划入组 66 人 · 首次发布于 2024 年 2 月 21 日

UPR pathway modulators (Proteostasis)

Wnt Pathway Stimulator (Almirall)

RIG-I like receptor pathway agonist (Kineta)

Pathway Therapeutics, Inc.

United States

Erasca

United States

Eledon Pharmaceuticals

United States

InflaRx Cuts 30% of Workforce, Deprioritizes COVID-19 Therapy to Focus on Immunology Pipeline

InflaRx Reports Encouraging Post-Hoc Analyses for Vilobelimab in Pyoderma Gangrenosum Despite Phase 3 Trial Termination

Mirador Therapeutics Licenses KP-301, a Long-Acting Anti-C5a Antibody, Expanding into ANCA-Associated Vasculitis